Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 25:12:1105745.
doi: 10.3389/fonc.2022.1105745. eCollection 2022.

Research progress of bone metastases: From disease recognition to clinical practice

Wenbo Yang  1 , Qing Pan  1 , Fuhua Huang  1 , Hongzhi Hu  1 , Zengwu Shao  1
Affiliations
Review

Research progress of bone metastases: From disease recognition to clinical practice

Wenbo Yang et al. Front Oncol. .

Abstract

Bone metastases, as one of the common types of metastatic tumors, have a great impact on the survival period and quality of life of patients. Bone metastases are usually characterized by bone destruction. Skeletal related events caused by bone destruction often lead to pain, pathological fractures and even paralysis. In this review, we provide a detailed explanation of bone metastases from the epidemiology, clinical features, pathogenesis, and recently developed clinical treatment viewpoints. We concluded that the incidence of bone metastases is increasing gradually, with serious clinical symptoms, complex pathogenesis and diverse clinical treatment. Tumor cells, immune cells, osteoblasts/osteoclasts and other cells as well as cytokines and enzymes all play a key role in the pathogenesis of bone metastases. We believe that the future treatment of bone metastases will be diversified and comprehensive. Some advanced technologies, such as nanomedicine, could be used for treatment, but this depends on understanding how disease occurs. With the development of treatment, the survival time and quality of life of patients will be improved.

Keywords: bone metastases; clinical practice; disease recognition; review; scope.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The role of different cell types in bone metastases.
Figure 2
Figure 2
Schematic diagram of the interaction between tumor cells and osteoblasts/osteoclasts in osteolytic bone metastases. In osteolytic lesions, tumor cells may secrete molecules such as DKK-1 to inhibit osteoblast Wnt signaling pathway and promote osteoclast function through RANK-RANKL signaling pathway. Osteoclasts may secrete IGF-1 and other molecules to promote tumor growth.DKK-1, Dickkopf-1; IFG-1, Insulin-like growth factor 1; RANK, Receptor Activator of NF-κB.
Figure 3
Figure 3
Typical mechanisms of action of key specific and non-specific immune cells in bone metastases. The red lines represent inhibitory effects.
Figure 4
Figure 4
The role of CAFs in the pathogenesis of bone metastases. The purple arrow represents an influence. EMT, epithelial-mesenchymal transition; PGE2, prostaglandin E2; EVs, extracellular vesicles; HGF, hepatocyte growth factor; VEGF, vascular endothelial growth factor.
See this image and copyright information in PMC

References

    1. Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, et al. . Bone metastases. Nat Rev Dis primers (2020) 6(1):83. doi: 10.1016/B978-0-323-47674-4.00056-6 - DOI - PubMed
    1. Ban J, Fock V, Aryee DNT, Kovar H. Mechanisms, diagnosis and treatment of bone metastases. Cells (2021) 10(11):2944. doi: 10.3390/cells10112944 - DOI - PMC - PubMed
    1. Migliorini F, Maffulli N, Trivellas A, Eschweiler J, Tingart M, Driessen A. Bone metastases: a comprehensive review of the literature. Mol Biol Rep (2020) 47(8):6337–45. doi: 10.1007/s11033-020-05684-0 - DOI - PubMed
    1. Cadieux B, Coleman R, Jafarinasabian P, Lipton A, Orlowski RZ, Saad F, et al. . Experience with denosumab (XGEVA®) for prevention of skeletal-related events in the 10 years after approval. J Bone Oncol (2022) 33:100416. doi: 10.1016/j.jbo.2022.100416 - DOI - PMC - PubMed
    1. Isogai N, Yagi M, Nishimura S, Nishida M, Mima Y, Hosogane N, et al. . Risk predictors of perioperative complications for the palliative surgical treatment of spinal metastasis. J orthopaedic Sci Off J Japanese Orthopaedic Assoc (2021) 26(6):1107–12. doi: 10.1016/j.jos.2020.09.005 - DOI - PubMed

LinkOut - more resources